Research · Sep 3, 2026
[SYRE] Sarepta Therapeutics Thesis 2026: A Duchenne-Muscular-Dystrophy Gene-Therapy Pioneer Navigates Elevidys Inflection
Sarepta Therapeutics, Inc. (SYRE), headquartered in Cambridge, Massachusetts (Boston-Cambridge-biotech-cluster + Charlestown-and-Burlington), is an RNA + gene-therapy + Duchenne Muscular Dystrophy (DMD) + emerging-Limb-Girdle Muscular Dystrophy (LGMD) + emerging-rare-disease biotech providing distinctive multi-cycle Elevidys + Exondys 51 + Vyondys 53 + Amondys 45 + emerging-LGMD-gene-therapy + emerging-rare-disease pipeline therapeutic services to DMD + emerging-LGMD + emerging-rare-disease patient base globally. Founded 1980 as AVI-BioPharma + multi-cycle AVI-BioPharma-RNA-PMO-antisense; 2012 substantial AVI-BioPharma rename to Sarepta Therapeutics + multi-cycle DMD-PMO-RNA-platform; 2016 substantial Exondys 51 FDA-accelerated-approval providing distinctive Exondys-51-DMD-PMO-RNA; 2019 Vyondys 53 FDA-accelerated-approval + 2021 Amondys 45 FDA-accelerated-approval; 2023 Elevidys initial-FDA-accelerated-approval (ambulatory-DMD-4-5-years) + 2024-Jun Elevidys expanded-label-FDA-approval (ambulatory-and-non-ambulatory-DMD-4+years-old); 2024 Roche-Sarepta-Elevidys ex-US strategic-partnership; 2024-Q4-2025 substantial Elevidys-safety + Vivacell-gene-therapy-deaths-and-Elevidys-related-deaths + emerging-FDA-investigation + emerging-FDA-pause. Under CEO Doug Ingram (since 2017, prior longtime Allergan + Chase Pharmaceuticals executive), FY2025 closes with selected various aggregate revenue ~$2.20-2.55B, operating income ~$50-180M, net income ~$0-130M, EPS ~$0-1.35, substantial cash ~$1.0-1.4B, and ~100M shares outstanding. The first deep-dive — Elevidys-gene-therapy + Exondys-Vyondys-Amondys-PMO-RNA + emerging-LGMD franchise — covers entire DMD + emerging-LGMD + emerging-rare-disease business + Sarepta-Therapeutics-and-Elevidys-and-PMO-RNA positioning. Elevidys (delandistrogene-moxeparvovec AAVrh74-gene-therapy) lead-asset + 2023 initial-FDA + 2024-Jun expanded-label-FDA-approval providing distinctive Elevidys-launch-ramp + 2024-Q4-Elevidys-safety + Vivacell-gene-therapy-deaths-and-Elevidys-related-deaths + emerging-FDA-investigation. Exondys 51 (eteplirsen exon-51-skipping DMD-PMO-RNA), Vyondys 53 (golodirsen exon-53-skipping), Amondys 45 (casimersen exon-45-skipping). Emerging-LGMD pipeline (LGMD-2E + LGMD-2D + emerging-rare-disease + emerging-multi-cycle-LGMD-gene-therapy). Multi-cycle Roche-Sarepta-Elevidys ex-US-strategic-partnership providing Elevidys ex-US-commercialization. Customer base: US + EU + emerging-multi-jurisdiction DMD + emerging-LGMD + emerging-rare-disease patient-population. Competes with PTC Therapeutics (PTCT Translarna + Emflaza most-direct-DMD-comp), Solid Biosciences (SLDB emerging-DMD-gene-therapy), REGENXBIO (RGNX most-direct-AAV-gene-therapy-platform-comp), Voyager (VYGR), uniQure (QURE most-direct-AAV-comp + Hemgenix-hemophilia), Bluebird Bio (BLUE), Krystal Biotech (KRYS Vyjuvek), Vertex (VRTX + CRISPR Therapeutics Casgevy most-direct-emerging-Casgevy-comp), CRISPR Therapeutics (CRSP), Editas (EDIT), Intellia (NTLA), Beam (BEAM), Prime Medicine (PRME), Generation Bio (GBIO), Rocket Pharma (RCKT), Ultragenyx (RARE); Roche (most-direct-Roche-partnership), Pfizer (PFE emerging-DMD-gene-therapy), Novartis (NVS Zolgensma SMA-gene-therapy), Spark Therapeutics (Roche-acquired Luxturna). The second deep-dive — Doug-Ingram + multi-decade-Sarepta-and-PMO-RNA + Elevidys-gene-therapy-and-strategic-acquisition-target compounder thesis — covers Doug-Ingram-CEO + Allergan + Chase Pharmaceuticals + large-pharma expertise, Sarepta-Therapeutics-and-Elevidys + PMO-RNA + emerging-LGMD platform, multi-cycle Roche-ex-US-Elevidys-strategic-partnership, post-2024-Q4-Elevidys-safety + emerging-FDA-investigation environment, emerging-strategic-acquisition-target potential (Roche + emerging-pharma-acquirer interest). Multi-decade compounder thesis combines Sarepta-Therapeutics-and-AVI-BioPharma ~45+ year heritage, Elevidys + Exondys + Vyondys + Amondys + emerging-LGMD pipeline, multi-cycle Roche-Sarepta-Elevidys-ex-US-partnership, Doug Ingram + Allergan + Chase Pharmaceuticals expertise, cash-rich + emerging-deleveraging balance sheet, emerging-strategic-acquisition-target potential — partially-offset by post-2024-Q4-Elevidys-safety + emerging-FDA-investigation. Capital position is cash-rich, emerging-deleveraging, multi-cycle-Elevidys-and-emerging-FDA-investigation-stress: cash + investment-portfolio ~$1.0-1.4B, modest convertible-debt ~$1.0-1.2B, $1.0-1.4B liquidity, FCF emerging-modestly-positive-to-modestly-negative, no dividend, no buyback, ~100M shares. At ~$24-65 per share, equity value ~$2.4-6.5B, EV ~$2.4-6.3B. Base case: Elevidys-launch + Elevidys-safety-resolved + FDA-investigation-resolved + Roche-ex-US-launch + Exondys-Vyondys-Amondys + emerging-LGMD + revenue $2.30-2.80B + EPS $0.50-1.50 + ~10-30% return. Bull case: Elevidys-launch substantially-recovers + Roche-ex-US-launch substantially-positive + emerging-LGMD inflects + emerging-strategic-acquisition-target (Roche + pharma-acquirer interest) + revenue $2.80-3.50B + EPS $1.50-3.50 + re-rate 25-40x + 75-200%+ return + takeout-premium-upside. Bear case: emerging-Elevidys-FDA-pause + FDA-investigation-adverse + Elevidys-launch-stalls + Exondys-Vyondys-Amondys disappoints + revenue $1.80-2.20B + EPS $(0.50)-0.30 + de-rate 10-15x + flat-to-substantially-negative + existential Elevidys-safety-risk.